Press Releases

Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data observed Single dose of lonvo-z freed most patients from both attacks and ongoing therapy for six-month efficacy evaluation period, demonstrating its potential to be the first and only one-time HAE treatmentRolling biologics license application (BLA) submission initiated with the U.S. Food and Drug Administration (FDA); anticipate U.S. launch in the first half of 2027, if approvedIntellia to host webcast today at 8:00 a.m. ET CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical comp

Valmont® Industries, Inc. (NYSE:VMI), a global leader that provides products and solutions to support vital infrastructure and advance agricultural productivity, today announced that management will participate in Gabelli's 17th Annual Value Investor Conference in Omaha, NE. Avner M. Applbaum, President and Chief Executive Officer and Renee Campbell, Senior Vice President, Capital Markets and Risk, will participate in a fireside chat at 10:30 AM CT on Friday, May 1, 2026. Investors interested in accessing the Company's presentation may register to access the live event here. All registrants will receive a link to the event upon registration. About Valmont Industries, Inc. For more than

Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient access and improve lives Acquisition is expected to be immediately accretive to Ligand adjusted EPS; Ligand increases 2026 adjusted EPS guidance to $8.50-$9.501 and expects the transaction to be accretive by $1.50 per share to adjusted EPS in 20272 Ligand to hold investor call at 8:00 a.m. ET today JUPITER, Fla. and EMERYVILLE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporate

WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced the completion of enrollment in the PreciSION CF Phase 2a proof-of-concept (POC) trial. This trial is evaluating SION-719, a first-in-class nucleotide binding domain 1 (NBD1) stabilizer, when added to Trikafta® (elexacaftor/tezacaftor/ivacaftor), the current standard of care (SOC) in CF. Sionna anticipates data from the PreciSION CF trial in the summer of 2026. "Completion of enrollment in our PreciSION CF proof-of-concept trial represents a significant m

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced it has initiated a rolling submission of a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of lonvo-z (formerly known as NTLA-2002) for hereditary angioedema (HAE). Designed as a one-time treatment that is administered in an outpatient setting, lonvo-z is an in vivo CRISPR gene editing candidate that is intended to inactivate the kallikrein B1 (KLKB1) gene to permanently lower kallikrein and bradyki

RALEIGH, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Martin Marietta Materials, Inc. (NYSE:MLM) (Martin Marietta or the Company) a leading national supplier of aggregates and other building materials, today announced the appointment of Chris Samborski as Executive Vice President and Chief Operating Officer, effective May 1, 2026. Mr. Samborski has extensive experience leading operating and finance teams. He most recently served as President of Martin Marietta's West and Specialties Divisions, where he was responsible for the overall operations and strategic direction of those business units. Under his leadership, both the West and Specialties Divisions achieved significant growth and success

― Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC) reduction ― ― Fulcrum plans to initiate a potential registration-enabling trial in the second half of 2026 ― ― Dosed first patient in an open-label, long-term dosing trial evaluating the long-term safety and durability of response to pociredir in participants previously enrolled in the PIONEER trial ― ― Appointed Josh Lehrer, M.D., M.Phil., FACC, an experienced leader in sickle cell disease drug development, to the Board of Directors ― ― Chief Financial Officer, Alan Musso

$225 million funded at closing, with an additional $225 million warrant tranche Financing funds operations through anticipated Phase 3 MASH 52-week data readout Financing was led by Deep Track Capital, with participation from TCGX, Viking Global Investors, RA Capital Management, and other new and existing investors GAITHERSBURG, Md., April 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced the closing of its previously announced underwritten public offering consisting of (i) 64,250,000 shares of its common stock and 64,250,000 accompanying common stock warra

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX:OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced WM Technology, Inc. (OTCQX:MAPS), the operator of Weedmaps, a leading cannabis marketplace for consumers, has been approved to trade on the OTCQX® Best Market. WM Technology, Inc. begins trading today on OTCQX under the symbol "MAPS." U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. Trading on the OTCQX Market offers companies efficient, cost-effective access to the U.S. capital markets. Streamlined market requirements for OTCQX are desig

SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the Company will host a key opinion leader (KOL) webinar to discuss data from an investigator-initiated trial on onvansertib's single-agent clinical activity in chronic myelomonocytic leukemia (CMML). The webinar will take place on Thursday, April 30th, 2026, at 11:00 a.m. ET. The webinar will feature KOL Mrinal Patnaik, MBBS, a physician scientist with the Division of Hematology, Department of Internal Medicine at Mayo Clinic, Minnesota. He is the Chair of the Acute

GXO brand to be featured on the No. 31 Arrow McLaren Chevrolet piloted by Ryan Hunter-Reay at 110th Running of the Indianapolis 500 GREENWICH, Conn. and INDIANAPOLIS, April 27, 2026 (GLOBE NEWSWIRE) -- GXO Logistics (NYSE:GXO), the world's largest pure‑play contract logistics provider, today announced its role as an Official Partner of the Arrow McLaren IndyCar Team, supporting the entry of the No. 31 Arrow McLaren Chevrolet driven by Ryan Hunter‑Reay at the 110th Running of the Indianapolis 500 next month. GXO CEO Patrick Kelleher, said: "At GXO, teamwork, precision and performance at speed define who we are. Like racing, the most successful logistics operations are built on trust, seam

SHENZHEN, China, April 27, 2026 (GLOBE NEWSWIRE) -- Recently, MoonFox Data showcased its industry-leading capabilities at the Neudata Hong Kong Summit, the premier event for institutional investors seeking a sophisticated edge through alternative data. As a dominant force in China's data intelligence landscape, MoonFox Data engaged with elite hedge funds and quantitative analysts to demonstrate how high-frequency signals drive superior investment outcomes. Keynote: Bridging Local Signals and Earnings Alpha Joken Liu, Product Director at MoonFox Data, delivered a high-impact presentation titled "China-Specific Alternative Data: From Local Signals to Earnings Forecasts." He showcased MoonF

BEDFORD, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in May 2026. Upcoming Investor Conferences: Bank of America Health Care Conference 2026:Date: Tuesday, May 12, 2026Fireside Chat: 3:40 – 4:10 PM PDTPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Las Vegas, NV Stifel 2026 Virtual Ophthalmology Forum:Date: Tuesday, May 26, 2026Fireside Chat: 2:30 – 2:55 PM EDTPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation:

CHATTANOOGA, Tenn., April 27, 2026 (GLOBE NEWSWIRE) -- Astec Industries, Inc. (NASDAQ:ASTE) announced that its Board of Directors declared a quarterly dividend of $0.13 per share. The dividend is to be paid on or about May 29, 2026, to shareholders of record as of the close of business on May 13, 2026. About ASTEC Astec is a manufacturer of specialized equipment for asphalt road building, aggregate processing and concrete production. Astec's manufacturing operations are divided into two primary business segments: Infrastructure Solutions that includes road building, asphalt and concrete plants, thermal and storage solutions; and Materials Solutions that includes our aggregate processing

Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Further MASH development to be undertaken only upon securing non-dilutive funding Sagimet to host a KOL event and webcast, April 30 at 2 pm ET SAN MATEO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today provided strategic and corporate updates. "Building on the recent successful Phase 3 clinical trial in China of our

Industry Visionaries Gary Vaynerchuk and Shelly Palmer to Headline Three-Day Event in San Antonio NielsenIQ (NYSE:NIQ), a global leader in consumer intelligence, will host its annual C360 event, June 8–11, 2026, at the JW Marriott San Antonio Hill Country Resort & Spa in San Antonio, Texas. This year's event centers around the theme "Built for the Future," reflecting NIQ's commitment to helping brands and retailers lead in a world that is moving faster than ever and build genuine organizational readiness for what comes next. NIQ's annual signature event will bring together leaders across retail, manufacturing, tech, and media for keynote presentations, expert-led breakout sessions, and

D-Wave Quantum Inc. (NYSE:QBTS) ("D-Wave" or the "Company"), the only dual-platform quantum computing company providing both annealing and gate-model systems, software and services, today announced that management will be participating in the following investor conferences: Needham's 21st Annual Needham Technology, Media & Consumer Conference on May 14, 2026, attending virtually J.P. Morgan's 2026 Global Technology, Media and Communications Conference on May 20, 2026 in Boston Canaccord Genuity's Virtual Quantum Symposium on May 21, 2026, attending virtually TD Cowen's 54th Annual Technology, Media & Telecom Conference on May 28, 2026 in New York City Baird's 2026 Global Cons

FREUDENSTADT, Germany, April 27, 2026 (GLOBE NEWSWIRE) -- SCHMID Group N.V. (NASDAQ:SHMD) (the "Company" or "SCHMID"), a global leader in providing solutions to the high-tech electronics, glass, and energy systems industries, today provides an update on its operational development following the completion of the first quarter of 2026. Operational Update for the first quarter ended March 31, 2026 In the first quarter of 2026, the Company recorded order intake of €13.6 million and generated revenues of €18.2 million. As in prior years, the first quarter reflects generally the softest period in terms of order intake and revenue contribution. The order book stood at €49 million at the en

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of patients with rare hematological disorders, today announced that Josh Lehrer, M.D., M.Phil., FACC, has been appointed to its Board of Directors as an independent director. Dr. Lehrer is a physician-scientist and biotechnology executive with more than two decades of clinical development experience across all stages of drug development. He currently serves as Chief Executive Officer and a member of the board of directors of Marea Therapeutics, a clinical-stage biotechnology company

AECOM (NYSE:ACM), the trusted global infrastructure leader, today announced it has been selected for a multiple-award environmental services contract by the U.S. Army Corps of Engineers (USACE), Baltimore District. This contract vehicle enables AECOM to deliver innovative environmental remediation solutions that tackle complex cleanup challenges, with a particular focus on reducing hazardous contaminants through site mitigation and remediation services, while supporting USACE and its customers in safeguarding communities and ecosystems. "For more than 40 years, AECOM has proudly partnered with the USACE Baltimore District to advance environmental cleanup initiatives that protect communiti